Embera is developing the first medication that treats addiction by moderating activity in the stress response system.

EMB-001 may potentially reduce the cravings and loss of control that drive addiction by uniquely targeting multiple pathways, to maximize potential efficacy more than either drug used alone. A therapy that breaks these barriers and results in long term abstinence and recovery would be a significant contribution to the treatment of a broad range of addictions.

Media & Publications

,

Embera NeuroTherapeutics' Chief Medical Officer, Michael Detke, to Moderate Panel on the Neuroscience of Addiction at BIO CEO & Investor Conference

/
Michael Detke, M.D., Ph.D., Embera’s Chief Medical Officer, will moderate the “Neuroscience of Addiction: Levers to Attack the Opioid Abuse Crisis” panel at 2018 BIO CEO & Investor Conference. The panel will be held on Tuesday, February 13, 2018, at 9 a.m. EST at the New York Marriott Marquis in New York City.
,

Embera NeuroTherapeutics to Present at the 10th Annual Biotech Showcase

/
Embera NeuroTherapeutics's President and Chief Executive Officer, Bob Linke, and Chief Medical Officer, Michael Detke, will present at the 10th Annual Biotech Showcase on Monday, January 8, 2018 at 10:00 a.m. Pacific time.
,

Embera NeuroTherapeutics to Present at the 2017 BIO Investor Forum

/
Embera NeuroTherapeutics, Inc. today announced that Bob Linke, the Company’s President and CEO and Michael Detke, M.D., Ph.D., the Company’s Chief Medical Officer, will present at the 2017 BIO Investor Forum on Tuesday, October 17, 2017 at 10:45 a.m. Pacific time.